Download PDFPDF

Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Alternative antithrombotic to conventional unfractionated heparin
    • Girish Gupta, Neonatologist
    • Other Contributors:
      • Gupta G, Sondhi V, Kinley T, Rohini PV

    Dear Editor

    It was a pleasure to go through the article “Use of low molecular mass heparin (Enoxaparin) in newborn infants: a prospective cohort study of 62 patients” by W. Streif et al.[1]

    In present setting in which increasingly preterms and extremely low birth weight babies are being salvaged, the degree of intervention in form of peripherally inserted central catheters and other modalities o...

    Show More
    Conflict of Interest:
    None declared.